Healthcare - Press Releases

InterCure Logo (PRNewsfoto/InterCure Ltd.)

Highlights:

CHANDLER, Ariz., Feb. 12, 2025 /PRNewswire/ --Embark Behavioral Health, a leader in youth and young adult mental health care, is reaffirming its commitment to creating joy and healing generations. Under the leadership of Scott Filion, CEO, and Dr. Sharnell Myles, Psy.D., Chief Clinical Officer, the company is fortifying its mission through a revitalized clinical leadership team and expanding their current services to offer integrated mental health.

OMAHA, Neb., Feb. 12, 2025 /PRNewswire/ -- IHS, LLC., a leading business acquisitions and management firm, along with its physician partners, proudly announces the successful acquisition of BC Healthcare, a distinguished specialty medical practice recognized for its advanced healthcare services. This strategic acquisition marks a significant milestone in IHS, LLC.'s commitment to expanding high-quality, patient-centered care and elevating healthcare standards in Omaha, Nebraska, and beyond.

PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ --Palindrome Technologies has been recognized as an official testing facility for the IEEE Medical Device Cybersecurity Certification Program, positioning the company at the forefront of medical device security. This certification program, launched in 2023 by the IEEE 2621 Conformity Assessment Committee (CAC), offers a comprehensive evaluation process tailored specifically for medical devices in an increasingly connected healthcare landscape.

HONG KONG, Feb. 12, 2025 /PRNewswire/ --Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed PD-1/CTLA-4 bispecific antibody, cadonilimab. This study is evaluating the efficacy of cadonilimab compared to sugemalimab (PD-L1) as a consolidation therapy for patients with locally advanced, non-resectable, non-small cell lung cancer (NSCLC) who have not experienced disease progression following concurrent or sequential chemoradiotherapy.

NEW YORK, LONDON, MNCHEN und NEU-DELHI, 13. Februar 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG), gibt die Ernennung von Dr. Massimo Cristofanilli, MD, zum strategischen Berater bekannt. DCG ist ein weltweit fhrendes Unternehmen im Bereich der nicht-invasiven Krebsdiagnostik. Mit diesem Schritt unterstreicht DCG sein Engagement fr die Weiterentwicklung der Krebsfrherkennung und Przisionsmedizin.

CHENGDU, China, Feb. 12, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025,Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd "Kelun-Biotech" will present efficacy and safety results from the Phase 1/2 KL264-01/MK-2870-001 study (NCT04152499) of its anti-TROP2ADC sacituzumab tirumotecan (sac-TMT, formerly SKB-264/MK-2870) as monotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (UC) who progressed on or after prior anti-cancer therapies. These findings will be presented in a poster session on February 14, 2025, local time (Abstract #796).

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).

TOKYO, Feb. 13, 2025 /PRNewswire/ --Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been dosed atKeio University Hospital. RV-001 utilizes adeno-associated virus (AAV) vectors to deliver a unique functional gene encoding "Chimeric Rhodopsin", a light-driven G-protein activation mechanism to re-establish light activation in retinal interneurons. The goal is to expand light sensitivity to retinal interneurons via an intravitreal injection of RV-001. This milestone marks the initiation of the world's first clinical trial of optogenetic gene therapy, which leverages a proprietary "Chimeric Rhodopsin" for patients with retinitis pigmentosa (RP). "Over 2 million people worldwide suffer photoreceptor loss in retinitis pigmentosa, resulting in severe vision loss and eventual blindness" said, CEO and Ophthalmologist Yusaku Katada, MD, PhD. "Our "chimeric rhodopsin" approach has broad potential to alter light sensitivity across multiple subtypes of RP patients.[1] We are continuing to advance the Phase I/II trial to assess safety, light-activation and light-sensitivity in these patients, post-administration of our lead gene therapy product RV-001."

VADUZ, Liechtenstein, Feb. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that U.S. FDA has completed its review of the PMA Module 2 submission and provided its feedback, in which the company sees no barrier for responding.

SHANGHAI and HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that XPOVIO (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM) who have received at least two prior therapies, has been approved for reimbursement in Taiwan. Starting from March 1, 2025, XPOVIO will be officially included in the NHI drug reimbursement scheme.

Southern Star sets itself apart in the CRO market through a unique combination of trust, operational advantages, deep industry expertise, and a strong commitment to local resources.

SEOUL, South Korea, Feb. 12, 2025 /PRNewswire/ -- LG Chem is entering the global market with eco-friendly raw materials derived from vegetable oils. The company announced that it will commence the production of bio-acrylic acid in the second quarter of this year. Production capacity shall ramp up to 100 metric tons (MT) of prototype annually.

HO CHI MINH CITY, Vietnam, Feb. 13, 2025 /PRNewswire/ -- XDENT LAB, one of the leading providers in the field of Removable Denture manufacturing in Vietnam, has officially announced the expansion of its production facility, making it the largest in the country. This strategic move not only marks a significant leap for XDENT LAB in the dental industry but also reinforces its pioneering position in Lab-to-Lab services, targeting the U.S. market.

MAILAND, 13. Februar 2025 /PRNewswire/ -- Newronika, ein weltweit fhrendes Unternehmen im Bereich der fortgeschrittenen Tiefenhirnstimulation, freut sich, den erfolgreichen Abschluss seiner Finanzierungsrunde der Serie B in Hhe von 13,6 Mio. EUR bekannt zu geben. Die Finanzierung wurde von einem neuen Investor, der Fondazione ENEA Tech e Biomedical, gefhrt, mit zustzlicher Beteiligung der bestehenden Investoren Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital und F3F.

MILAN, Feb. 13, 2025 /PRNewswire/ -- Newronika, a global leader in advanced deep brain stimulation, is pleased to announce the successful closing of its EUR13.6 million Series B funding round. The financing was led by a new investor, Fondazione ENEA Tech e Biomedical, with additional participation from existing investors Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F.

MILAN, 13 fvrier 2025 /PRNewswire/ -- Newronika, leader mondial de la stimulation crbrale profonde avance, a le plaisir d'annoncer la clture russie de son tour de financement de srie B de 13,6millions d'euros. Le financement a t men par un nouvel investisseur, la Fondazione ENEA Tech e Biomedical, avec une participation supplmentaire des investisseurs existants Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital et F3F.

Global Financial Market Review (GFM) is a dedicated online news aggregation portal specializing in financial market news and industry updates. It combines original editorials with curated content from global news providers, reaching over 14 million readers annually. With a focus on reliability and depth, GFM has positioned itself as a trusted source in the financial sector, boasting a strong social media presence with over 180,000 Twitter followers.

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The fundus camera market and it is set to grow by USD 174.65 thousand from 2025 to 2029. However, the growth momentum will progressing at a CAGR of over 6.2% during the forecast period, according to Technavio. The fundus camera market is fragmented, and the vendors are seeking strong partnerships with automotive, industrial, and commercial companies to compete in the market.Allm Inc., Canon Inc., Carl Zeiss AG, Chongqing Bio Newvision Medical Equipment Ltd., CSO ITALIA, Epipole Ltd., Essilor Instruments USA, Forus Health Pvt. Ltd., Haag Streit AG, Hongdee Ophthalmic Equipment, INTUVISION LABS, Kody Medical Electronics Pvt. Ltd., Kowa Co. Ltd., Marco, Mediworks, New Vision, NIDEK Co. Ltd., Optitech Eye Care, Optomed Oyj, PHELCOM, Remidio Innovative Solutions Pvt. Ltd., Revenio Group Oyj, Topcon Corp., VISIONIX USA INC., Volk Optical, and Zimed Healthcare Inc. Are some of the major market participants -.To know about the vendor offerings - Request a sample report

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Report on how AI is redefining market landscape - The global health and wellness food marketsize is estimated to grow by USD 627.6 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 9.8% during the forecast period. Increasing adoption of healthy eating habits is driving market growth, with a trend towards adoption ofprebiotic and probiotic food. However, high cost of health and wellness food poses a challenge. Key market players include Amys Kitchen Inc., Archer Daniels Midland Co., Bobs Red Mill Natural Foods Inc., Chobani Global Holdings LLC, Clif Bar and Co., Dairy Farmers of America Inc., Danone SA, Dr. Schar, Fifty50 Foods, General Mills Inc., Glanbia plc, GSK Plc, Kellogg Co., London Foods Ltd., Mars Inc., Mondelez International Inc., Nestle SA, PepsiCo Inc., United Natural Foods Inc., and Yakult Honsha Co. Ltd..

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The globalpharmaceuticals wholesale and distribution market size is estimated to grow by USD 896.5 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.45% during the forecast period. Growing global pharmaceutical salesis driving market growth,with a trend towardsemergence of drones in pharmaceuticals wholesale and distribution. However,increased complexities due to time-bound deliveries and customization of supply chain poses a challenge.Key market players include A.F. Hauser Pharmaceutical Inc., Alfresa Holdings Corp., AmerisourceBergen Corp., Attain Med Inc., Cardinal Health Inc., China Resources Pharmaceutical Group Ltd., Dakota Drug Inc., FFF Enterprises Inc., J M Smith Corp., McKesson Corp., MEDIPAL HOLDINGS CORP., Medline Industries LP, Morris and Dickson Co. LLC, Mutual Drug, Owens and Minor Inc., PHOENIX Pharmahandel GmbH and Co KG, Shanghai Fosun Pharmaceutical Group Co. Ltd., Sinopharm Group Co. Ltd., SUZUKEN CO. LTD., and The Cigna Group.

NOVATO, Calif., Feb. 11, 2025 /PRNewswire/ -- The sleek, modern quartz countertops that have become a staple of American homes are hiding a deadly secret. Hundreds of workers responsible for cutting and fabricating these fashionable artificial stone countertops are falling ill with acceleration silicosis, a fatal and incurable lung disease caused by inhaling toxic, nano-sized particles of silica dust and other toxins.

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global health and wellness marketsize is estimated to grow by USD 2.06 trillion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 7.1% during the forecast period. Increasing emphasis on promotion of health and wellness activities and programs is driving market growth, with a trend towards growing influence of thermal and mineral springs and spas. However, frequent product recalls poses a challenge. Key market players include Adidas AG,Amway Corp., Bayer AG, Beiersdorf AG, Core Health and Fitness LLC, Danone SA, David Lloyd Leisure Ltd., General Mills Inc., Glooko Inc., Herbalife International of America Inc., Johnson Health Tech Co. Ltd., LOreal SA, Nestle SA, Novo Nordisk AS, Ogilvie and Co., PepsiCo Inc., RSG Group GmbH, Shiseido Co. Ltd., The Procter and Gamble Co., Unilever PLC, and Vitabiotics Ltd..

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The globalmedical tourism market size is estimated to grow by USD 85.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 32.11% during the forecast period. Availability of low-cost treatment optionsis driving market growth,with a trend towardsgrowing focus on technological advancements. However,lack of advanced infrastructure in developing nations poses a challenge. Key market players include Anadolu Medical Center, Apollo International Ltd., Asian Heart Institute, Asian institute of medical sciences, Asklepios Kliniken GmbH and Co. KGaA, Athina Global Health, Bangkok Chain Hospital Public Co. Ltd, Bangkok Dusit Medical Services Public Co. Ltd., BNH Medical Centre Co. Ltd., Bumrungrad Hospital Public Co. Ltd, Clalit Research Institute, Clemenceau Medical Center, Dr. B. L. Kapur Memorial Hospital, Global Health Ltd., IHH Healthcare Berhad., Min Sheng General Hospital, Raffles Medical Group Ltd, Spire Healthcare Group Plc, The Cleveland Clinic Foundation, and The Johns Hopkins Health System Corp..